Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T16721 |
Ralimetinib
LY2228820 |
Others | Others |
Ralimetinib selectively inhibits phosphorylation of MK2 (Thr334) and has no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc. Ralimetinib is an effective and selective, ATP-competitive inhibitor of p38 MAPK α/β (IC50s: 5.3 and 3. | |||
T6047 |
Ralimetinib dimesylate
LY2228820 dimesylate,Ralimetinib,LY2228820,Ralimetinib Mesylate |
Apoptosis; p38 MAPK; Autophagy | Apoptosis; Autophagy; MAPK |
Ralimetinib dimesylate (LY2228820 dimesylate) 是一种选择性,ATP 竞争性的 p38 MAPK α/β抑制剂,IC50分别为5.3 和 3.2 nM。 |